Ablexis Announces Licensing Agreement with Corvidia Therapeutics
Ablexis grants rights to Corvidia to use the AlivaMab Mouse™ platform for research, development and potential commercialization of antibodies SAN DIEGO, Calif. – January 3, 2019 – Ablexis, LLC, a...
View ArticleClik here to view.
Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with...
Expanded rights enable broader use of AlivaMab Mouse platform SAN DIEGO, Calif. – January 17, 2019 – Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform...
View ArticleClik here to view.
Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US)
Ablexis grants rights to use the AlivaMab Mouse platform for research, development and potential commercialization of antibodies SAN DIEGO, Calif. – June 3, 2019 – Ablexis, LLC, a biopharmaceutical...
View ArticleClik here to view.
AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen
ADS to provide expertise and capabilities in antibody drug discovery SAN DIEGO, Calif. – September 16, 2019 – AlivaMab Discovery Services, LLC, a company providing custom human therapeutic antibody...
View ArticleAblexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to...
Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab Discovery Services, LLC ("ADS") and Berkeley Lights, Inc. today...
View ArticleAblexis Announces Further Expansion of Its Intellectual Property on AlivaMab®...
Fourteen new patents expand worldwide protection of the unique beneficial designs of AlivaMab Mouse and AlivaMab antibodies, and Ablexis' innovations in immunoglobulin transgene engineering SAN...
View ArticleAblexis Announces Multi-Target License Agreement with Tanabe Research...
Ablexis grants rights to use the AlivaMab® Mouse platform for research, development and commercialization of antibodies SAN DIEGO, Calif. – May 4, 2021 – Ablexis, LLC, a biopharmaceutical company...
View ArticleAblexis and AlivaMab Discovery Services Announce Agreements with Almirall to...
Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies. AlivaMab Discovery Services will...
View ArticleAblexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug...
New platforms and capabilities further enable partners to advance better antibody drugs faster. SAN DIEGO, Calif. – November 15, 2022 – Ablexis, LLC (“Ablexis”), a biopharmaceutical company focused on...
View ArticleWest Coast Antibody HubXChange
September 23, 2024. San Francisco, CA The post West Coast Antibody HubXChange appeared first on Ablexis.
View Article